Results 81 to 90 of about 11,873,006 (292)

Effect of Growth Hormone (hGH) Replacement Therapy on Physical Work Capacity and Cardiac and Pulmonary Function in Patients with hGH Deficiency Acquired in Adulthood. [PDF]

, 1995
The effects of 6 months of replacement therapy with recombinant human GH (hGH) on physical work capacity and cardiac structure and function were investigated in 20 patients with hGH deficiency of adult onset in a double blind, placebo-controlled trial ...
Schopohl, Jochen, Nass, Ralf, Strasburger, Christian J., Klauss, Volker, Müller, Otto A., Huber, Rudolf M.   +5 more
core   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Growth Hormone (GH)-Releasing Peptide Stimulation of GH Release from Human Somatotroph Adenoma Cells: Interaction with GH-Releasing Hormone, Thyrotropin- Releasing Hormone, and Octreotide. [PDF]

, 1994
The synthetic hexapeptide GH-releasing peptide (GHRP; His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) specifically stimulates GH secretion in humans in vivo and in animals in vitro and in vivo via a still unknown receptor and mechanism.
Strasburger, Christian J., Renner, U., Müller, O., Stalla, G., Brockmeier, S., Schopohl, Jochen, Strasburger, C., Müller, Otto-Albrecht, Schopohl, J., Strasburger, C. J., Werder, K., Lange, M., Werder, K. von, Stalla, G. K., Müller, O. A.   +14 more
core   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

Early cessation and non-response are important and possibly related problems in growth hormone therapy: An OZGROW analysis

, 2016
Objective: To investigate growth hormone (GH) treatment and treatment cessation with respect to efficacy and efficiency. To identify factors that best classify or predict cessation type: completed treatment (CT), early cessation (EC), or non-response (NR)
Harris, M., Cutfield, W., Cotterill, A, Hughes, IP, Hughes, I., Harris, M, Rath, S, Cutfield, Wayne, Choong, C., Cotterill, A., Rath, S., Choong, C, Hofman, Paul, Atkinson, Helen, Hofman, P., Atkinson, H   +15 more
core   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

The exon3-deleted growth hormone receptor gene polymorphism (d3-GHR) is associated with insulin and spontaneous growth in short SGA children (NESGAS)

, 2017
Objective The effect of a common polymorphism in the Growth Hormone (GH) receptor (d3-GHR) gene on growth, metabolism and body composition was examined in short children born small for gestational age (SGA) on GH treatment.
Thankamony, Ajay, Dunger, David B., Mathilde Gersel Wegmann, Roche, Edna,, Ivarsson, Sten A., Roche, E, Ajay Thankamony, Hoey, Hilary,, Kirk, Jeremy, Ivarsson, Sten-A., Thankamony, A, Rikke Beck Jensen, Jeremy Kirk, Thankamony, Ajay,, Roche, Edna, Juul, Anders,, Söder, Olle, Jensen, Rikke Beck,, Wegmann, Mathilde Gersel, David B. Dunger, Ivarsson, Sten A.,, Ivarsson, Sten-A, Soder, O, Jensen, Rikke Beck, Juul, A, Guftar Shaikh, Söder, Olle,, Edna Roche, Hoey, Hilary, Hoey, H, Kirk, J, Dunger, DB, Kirk, Jeremy,, Dunger, David B, Sten-A. Ivarsson, Anders Juul, Ivarsson, S-A, Wegmann, MG, Hilary Hoey, Juul, Anders, Shaikh, Guftar, Wegmann, Mathilde Gersel,, Dunger, David B.,, Shaikh, Guftar,, Lund University., Shaikh, G, Olle Söder   +46 more
core   +1 more source

Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation [PDF]

, 2009
Background: Acromegaly, an orphan disease usually caused by a benign pituitary tumour, is characterised by hyper-secretion of growth hormone (GH) and insulin-like growth factor I (IGF-1).
Martin J Connock, Adi, Yaser, Sue Bayliss, Connock, Martin J, Yaser Adi, Moore, David J, Connock, Martin, Bayliss Sue, Adi Yaser, Connock Martin J, Moore David J, Bayliss, Sue, Moore, David; id_orcid, Yaser, A, Moore, David J., Dr., Connock, M., Adi, Y., Bayliss, Susan; id_orcid, David J Moore   +18 more
core   +3 more sources

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Effect of growth hormone treatment on circulating levels of NT-proBNP in patients with ischemic heart failure

, 2020
Growth hormone (GH) therapy in heart failure (HF) is controversial. We investigated the cardiovascular effects of GH in patients with chronic HF due to ischemic heart disease.In a double-blind, placebo-controlled trial, we randomly assigned 37 patients ...
Polte, Christian Lars,, Bobbio, Emanuele,, Hjalmarson, Åke,, Bollano, Entela,, Peterson, Magnus, Caidahl, Kenneth,, Isgaard, Jörgen,, Swedberg, Karl,, Cittadini, Antonio, Bengtsson, Bengt-Åke,, Ekelund, Jan, Karason, Kristjan,   +11 more
core   +1 more source